

# Lei Deng

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/440046/lei-deng-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

181  
citations

7  
h-index

11  
g-index

50  
ext. papers

280  
ext. citations

4.1  
avg, IF

2.58  
L-index

#	Paper	IF	Citations
43	Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 130-7	5.3	24
42	Circulating circRNA predicting the occurrence of hepatocellular carcinoma in patients with HBV infection. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 10216-10222	5.6	20
41	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. <i>Radiation Oncology</i> , <b>2019</b> , 14, 48	4.2	15
40	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , <b>2020</b> , 25, e701-e708	5.7	11
39	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , <b>2019</b> , 14, 106	4.2	10
38	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 397	4.8	10
37	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 144	4.8	8
36	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1918070	10.4	7
35	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , <b>2019</b> , 10, 1985-1990	4.5	6
34	A deep learning-based dual-omics prediction model for radiation pneumonitis. <i>Medical Physics</i> , <b>2021</b> , 48, 6247-6256	4.4	5
33	Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. <i>Oncotarget</i> , <b>2016</b> , 7, 66160-66169	3.3	4
32	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1499	5.3	4
31	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta Oncologica</i> , <b>2021</b> , 60, 627-634	3.2	4
30	Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells. <i>Translational Lung Cancer Research</i> , <b>2019</b> , 8, 760-774	4.4	4
29	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 814-823	3.2	4
28	Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3208-3215	3.2	3
27	CHST15 promotes the proliferation of TE-1 cells via multiple pathways in esophageal cancer. <i>Oncology Reports</i> , <b>2020</b> , 43, 75-86	3.5	3

26	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 244-250	5.3	3
25	Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , <b>2021</b> ,	4.9	3
24	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, 380-387	1.9	3
23	Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 227-234	3.2	3
22	Radiation pneumonitis complicated by <i>Pneumocystis carinii</i> in patients with thoracic neoplasia: a clinical analysis of 7 cases. <i>Cancer Communications</i> , <b>2019</b> , 39, 47	9.4	2
21	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. <i>Radiation Oncology</i> , <b>2020</b> , 15, 155	4.2	2
20	MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.. <i>International Journal of Biological Sciences</i> , <b>2022</b> , 18, 43-64	11.2	2
19	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 901	4.8	2
18	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2916-2923	3.2	2
17	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 799-806	3.2	2
16	A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. <i>Oncologist</i> , <b>2019</b> , 24, e914-e920	5.7	2
15	Transcriptome alteration spectrum in rat lung induced by radiotherapy. <i>Scientific Reports</i> , <b>2019</b> , 9, 197014.9	14.9	2
14	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2021</b> , 33, 53-60	3.8	2
13	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
12	Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. <i>Oncotarget</i> , <b>2016</b> , 7, 46536-46544	3.3	1
11	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 877	4.8	1
10	Treatment planning of volumetric modulated arc therapy and positioning optimization for hippocampal-avoidance prophylactic cranial irradiation. <i>Journal of Applied Clinical Medical Physics</i> , <b>2021</b> , 22, 15-23	2.3	1
9	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1831-1840	3.2	1

8	Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 575394	5.3	1
7	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 781340	5.3	0
6	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. <i>Clinical Medicine Insights: Oncology</i> , <b>2022</b> , 16, 11795549221080347	1.8	0
5	The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 732883	5.3	
4	The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15560- <del>e15560</del> <sup>e215560</sup>	2.2	
3	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 618776	5.3	
2	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma.. <i>Radiation Oncology</i> , <b>2022</b> , 17, 58	4.2	
1	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma.. <i>Translational Oncology</i> , <b>2022</b> , 19, 101379	4.9	